Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab as Adjunct to AR101 in Pediatric Peanut Allergy
NCT03682770Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing Dupilumab + AR101 with Placebo + AR101 (2 arms). Primary endpoint: Percentage of Participants Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC). Started Oct 2018; status: completed.
02
Drugs
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03682770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682770.